[Congressional Record Volume 167, Number 122 (Tuesday, July 13, 2021)]
[Senate]
[Page S4857]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]




                         SUBMITTED RESOLUTIONS

                                 ______
                                 

    SENATE RESOLUTION 298--DESIGNATING JULY 15, 2021, AS ``NATIONAL 
LEIOMYOSARCOMA AWARENESS DAY'' AND THE MONTH OF JULY 2021 AS ``NATIONAL 
                       SARCOMA AWARENESS MONTH''

  Ms. STABENOW submitted the following resolution; which was referred 
to the Committee on the Judiciary:

                              S. Res. 298

       Whereas sarcoma is a rare type of cancer that--
       (1) arises in the connective tissue of the body; and
       (2) accounts for approximately 1 percent of all newly 
     diagnosed cancers;
       Whereas the National Institutes of Health designates 
     sarcoma, which contains approximately 70 different subtypes, 
     as a rare form of cancer;
       Whereas sarcomas are largely resistant to current 
     chemotherapy agents, immunotherapy agents, and radiation 
     therapies, posing a formidable challenge for researchers and 
     specialists;
       Whereas sarcoma subtypes largely have not benefitted from 
     immunotherapies because of the complexity of the DNA, 
     genomes, and mutations associated with the many variations in 
     the sarcoma subtype landscape;
       Whereas leiomyosarcoma (referred to in this preamble as 
     ``LMS'') is a malignant, aggressive subtype of sarcoma 
     derived from smooth muscle cells typically of uterine, 
     gastrointestinal, or soft tissue origin that can metastasize 
     to the bone, spine, brain, and liver;
       Whereas the National Institutes of Health classifies LMS, 
     which encompasses at least 4 different LMS subtypes, as a 
     rare disease, accounting for approximately 15 percent of all 
     sarcomas;
       Whereas LMS primarily affects adults without regard to 
     gender;
       Whereas, with respect to LMS--
       (1) research and clinical trials remain complicated; and
       (2) survival and longevity remain difficult;
       Whereas multidisciplinary care coordination teams, because 
     of their expertise and experience, are critical to the health 
     of sarcoma and LMS patients;
       Whereas sarcoma and LMS research will--
       (1) allow medical professionals to improve the quality of 
     care for affected patients;
       (2) lead to better clinical outcomes; and
       (3) promote longer survival for patients; and
       Whereas increased education and awareness about sarcoma and 
     LMS will contribute to the well-being of the communities of 
     the United States: Now, therefore, be it
       Resolved, That the Senate--
       (1) designates July 15, 2021, as ``National Leiomyosarcoma 
     Awareness Day'';
       (2) designates the month of July 2021 as ``National Sarcoma 
     Awareness Month'';
       (3) recognizes the challenges faced by sarcoma and 
     leiomyosarcoma patients; and
       (4) commends the dedication of organizations, volunteers, 
     researchers, and caregivers across the United States working 
     to improve the quality of life of sarcoma and leiomyosarcoma 
     patients and their families.

                          ____________________